Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors.

Autor: Wittlinger F; Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany., Ogboo BC; Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA., Shevchenko E; Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' Eberhard Karls Universität Tübingen, 72076, Tübingen, Germany.; Tübingen Center for Academic Drug Discovery & Development (TüCAD2), 72076, Tübingen, Germany., Damghani T; Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA., Pham CD; Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA., Schaeffner IK; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA., Oligny BT; Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA., Chitnis SP; Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA., Beyett TS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.; Department of Pharmacology and Chemical Biology, Emory University School of Medicine, 5119 Rollins Research Center, 1510 Clifton Rd, Atlanta, GA, 30322, USA., Rasch A; Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany., Buckley B; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA., Urul DA; AssayQuant Technologies, Inc., Marlboro, MA, 01752, USA., Shaurova T; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA., May EW; AssayQuant Technologies, Inc., Marlboro, MA, 01752, USA., Schaefer EM; AssayQuant Technologies, Inc., Marlboro, MA, 01752, USA., Eck MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA., Hershberger PA; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA., Poso A; Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' Eberhard Karls Universität Tübingen, 72076, Tübingen, Germany.; Tübingen Center for Academic Drug Discovery & Development (TüCAD2), 72076, Tübingen, Germany.; School of Pharmacy, University of Eastern Finland, 70210, Kuopio, Finland., Laufer SA; Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076, Tübingen, Germany. stefan.laufer@uni-tuebingen.de.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' Eberhard Karls Universität Tübingen, 72076, Tübingen, Germany. stefan.laufer@uni-tuebingen.de.; Tübingen Center for Academic Drug Discovery & Development (TüCAD2), 72076, Tübingen, Germany. stefan.laufer@uni-tuebingen.de., Heppner DE; Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA. davidhep@buffalo.edu.; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA. davidhep@buffalo.edu.; Department of Structural Biology, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA. davidhep@buffalo.edu.

Publikováno v: Communications chemistry [Commun Chem] 2024 Feb 20; Vol. 7 (1), pp. 38. Date of Electronic Publication: 2024 Feb 20.

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).

Autor: Heppner DE; Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, New York 14260, United States.; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203, United States., Wittlinger F; Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany., Beyett TS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States., Shaurova T; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203, United States., Urul DA; AssayQuant Technologies, Inc., 260 Cedar Hill St., Marlboro, Massachusetts 01752, United States., Buckley B; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203, United States., Pham CD; Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, New York 14260, United States., Schaeffner IK; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States., Yang B; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States., Ogboo BC; Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, New York 14260, United States., May EW; AssayQuant Technologies, Inc., 260 Cedar Hill St., Marlboro, Massachusetts 01752, United States., Schaefer EM; AssayQuant Technologies, Inc., 260 Cedar Hill St., Marlboro, Massachusetts 01752, United States., Eck MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States., Laufer SA; Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany.; Tübingen Center for Academic Drug Discovery & Development (TüCAD2), 72076 Tübingen, Germany., Hershberger PA; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203, United States.

Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2022 Nov 10; Vol. 13 (12), pp. 1856-1863. Date of Electronic Publication: 2022 Nov 10 (Print Publication: 2022).

High responsiveness of wood anatomy to water availability and drought near the equatorial rear edge of Douglas-fir.

Autor: González-Cásares, Marcos¹ (AUTHOR), Camarero, J. Julio² (AUTHOR) jjcamarero@ipe.csic.es, Colangelo, Michele^2,3,4 (AUTHOR), Rita, Angelo^1,3 (AUTHOR), Pompa-García, Marín^2,4 (AUTHOR)

Publikováno v: Canadian Journal of Forest Research. 2019, Vol. 49 Issue 9, p1114-1123. 10p.

Erratum to: PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma.

Autor: Lin ST; Institute of Bioinformatics and Structural Biology, National Tsing Hua University, No. 101, Kuang-Fu Rd. Sec. 2, Hsin-chu, 30013, Taiwan., May EW, Chang JF, Hu RY, Wang LH, Chan HL

Publikováno v: Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2015 Jun; Vol. 72 (12), pp. 2411-3.

Reversible linkage of two distinct small molecule inhibitors of Myc generates a dimeric inhibitor with improved potency that is active in myc over-expressing cancer cell lines.

Autor: Wanner J; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America., Romashko D; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America., Werner DS; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America., May EW; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America., Peng Y; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America., Schulz R; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America., Foreman KW; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America., Russo S; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America., Arnold LD; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America., Pingle M; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America., Bergstrom DE; Purdue University, West Lafayette, Indiana, United States of America., Barany F; Department of Microbiology, Weill Cornell Medical College, New York, New York, United States of America., Thomson S; Coferon Inc, 25 Health Sciences Drive, Stony Brook, New York, United States of America.

Publikováno v: PloS one [PLoS One] 2015 Apr 15; Vol. 10 (4), pp. e0121793. Date of Electronic Publication: 2015 Apr 15 (Print Publication: 2015).